Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of hypercapnic acute respiratory failure with high-flow nasal cannula therapy: A narrative review.

Annals of intensive care·2026

Same author

Relation between initial hypothermia, course of the hypothermia and mortality in patients with septic shock: a post-hoc analysis of the SEPSISPAM randomized trial.

Annals of intensive care·2026

Same author

Prognosis of critically ill patients with severe acute kidney injury and high circulating dipeptidyl peptidase 3: a post hoc analysis of the AKIKI 2 trial.

Critical care (London, England)·2026

Same author

Neutrophils, not macrophages, aid phage-mediated control of pulmonary <i>Pseudomonas aeruginosa</i> infection.

Frontiers in immunology·2025

Same author

Use of rescue noninvasive ventilation for post-extubation respiratory failure.

Critical care (London, England)·2025

Same author

Total liquid ventilation in a porcine model of severe acute respiratory distress syndrome using a new generation of liquid ventilator.

Intensive care medicine experimental·2025

Search research articles

Related Experiment Video

Updated: May 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

New therapies for pneumonia.

Jean-Damien Ricard¹

¹Institut National de la Santé ET de la Recherche Médicale, Unité U722, UFR de Médecine, Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France. jean-damien.ricard@lmr.aphp.fr

Current Opinion in Pulmonary Medicine

|March 6, 2012

Summary

New nonantibiotic therapies show promise for treating acute respiratory infections caused by antibiotic-resistant bacteria. Research targets bacterial adhesion, communication, and virulence, with ongoing clinical studies yielding encouraging results.

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Related Experiment Videos

Last Updated: May 24, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Area of Science:

Microbiology
Infectious Diseases
Public Health

Background:

Acute respiratory tract infections (ARTIs) are a major global health concern, leading to significant mortality.
The rise of antibiotic-resistant bacteria, coupled with a scarcity of new antibiotics, poses a critical threat to public health.
Understanding bacterial pathogenesis provides novel targets for antimicrobial strategies beyond traditional antibiotics.

Purpose of the Study:

To review emerging nonantibiotic antimicrobial therapies for ARTIs.
To explore novel therapeutic targets in bacterial growth, metabolism, and virulence.
To assess the potential of these strategies in combating antibiotic resistance.

Main Methods:

Review of experimental leads targeting bacterial adhesion, communication, toxins, and virulence factors.
Investigation of bacteriophage therapy and vaccine strategies.
Analysis of preclinical and early clinical data for nonantibiotic approaches.

Main Results:

Promising results in inhibiting bacterial quorum sensing and adhesion using pilicides.
Successful prevention and treatment of Pseudomonas aeruginosa pneumonia with bacteriophages.
Effective protection against P. aeruginosa lung infections via mucosal vaccination and anti-PcrV antibodies.

Conclusions:

Nonantibiotic therapies demonstrate significant potential for clinical translation in treating ARTIs.
Ongoing clinical studies are evaluating these novel approaches.
Early findings suggest these strategies could offer viable alternatives to antibiotics against resistant pathogens.